Modified nanoparticles with cell-penetrating peptide and amphipathic chitosan derivative for enhanced oral colon absorption of insulin: preparation and evaluation

Drug Delivery

Volumn 23, Issue 6, 2016, Pages 2003-2014

  Guo, Feng ^a   Zhang, Mengyuan ^a   Gao, Yuan ^b   Zhu, Siqi ^b   Chen, Shuangxi ^b   Liu, Wenyu ^b   Zhong, Haijun ^b   Liu, Jianping ^a  

^a CHINA PHARMACEUTICAL UNIVERSITY   (China)

^b NANCHANG UNIVERSITY   (China)

Author keywords

Cell penetrating peptide; chitosan; insulin; nanoparticles; Tat

Indexed keywords

CELL PENETRATING PEPTIDE; CHITOSAN DERIVATIVE; DRUG CARRIER; NANOPARTICLE; PIG INSULIN; POLYGLACTIN; TECHNETIUM 99M; CHITOSAN; INSULIN; TECHNETIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; CACO 2 CELL LINE; CELL ADHESION; CELL TRANSPORT; CHEMICAL MODIFICATION; COLON ABSORPTION; COLON MUCOSA; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; EMULSION; EPITHELIUM CELL; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALE; MINIPIG; NONHUMAN; PRIORITY JOURNAL; RAT; RAT MODEL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STOMACH JUICE; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CACO-2 CELL LINE; CHEMISTRY; COLON; DRUG EFFECTS; METABOLISM; ORAL DRUG ADMINISTRATION; PIG; PROCEDURES;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CELL-PENETRATING PEPTIDES; CHITOSAN; COLON; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; INSULIN; NANOPARTICLES; RATS; SWINE; TECHNETIUM;

EID: 84975122972     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2015.1048489     Document Type: Article

References (65)

1. E.Arbit. (2004). The physiological rationale for oral insulin administration. Diabetes Technol Ther 6:510–17
2. P.Artursson, T.Lindmark, S.S.Davis, L.Illum. (1994). Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm Res 11:1358–61
3. M.Ashford, J.T.Fell. (1994). Targeting drugs to the colon: delivery systems for oral administration. J Drug Target 2:241–58
4. S.H.Bakhru, S.Furtado, A.P.Morello, E.Mathiowitz. (2013). Oral delivery of proteins by biodegradable nanoparticles. Adv Drug Deliv Rev 65:811–21
5. A.Bayat, F.A.Dorkoosh, A.R.Dehpour,. (2008). Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int J Pharm 356:259–66
6. A.Bernkop-Schnürch, S.Dünnhaupt. (2012). Chitosan-based drug delivery systems. Eur J Pharm Biopharm 81:463–9
7. M.C.Bonferoni, G.Sandri, S.Rossi,. (2009). Chitosan and its salts for mucosal and transmucosal delivery. Expert Opin Drug Deliv 6:923–39
8. A.Chauhan, A.Tikoo, A.K.Kapur, M.Singh. (2007). The taming of the cell penetrating domain of the HIV Tat: myths and realities. J Control Release 117:148–62
9. M.C.Chen, K.Sonaje, K.J.Chen, H.W.Sung. (2011). A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 32:9826–38
10. F.Chen, Z.R.Zhang, F.Yuan,. (2008). In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int J Pharm 349:226–33
11. F.D.Cui, K.Shi, L.Q.Zhang,. (2006). Biodegradable nanoparticles loaded with insulin–phospholipid complex for oral delivery: preparation, in vitro characterization and in vivo evaluation. J Control Release 114:242–50
12. C.Damgé, P.Maincent, N.Ubrich. (2007). Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release 117:163–70
13. L.M.Ensign, R.Cone, J.Hanes. (2012). Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv Drug Deliv Rev 64:557–70
14. 99mTc labelled poly lactic acid microspheres for diagnostic radioembolization. J Microencapsul 17:509–18
15. C.Foged, H.M.Nielsen. (2008). Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv 5:105–17
16. A.Gulbake, S.K.Jain. (2012). Chitosan: a potential polymer for colon-specific drug delivery system. Expert Opin Drug Deliv 9:713–29
17. M.Hällbrink, A.Florén, A.Elmquist,. (2001). Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 1515:101–9
18. S.Haupt, A.Rubinstein. (2002). The colon as a possible target for orally administered peptide and protein drugs. Crit Rev Ther Drug Carrier Syst 19:499–551
19. B.He, P.Lin, Z.R.Jia,. (2013). The transport mechanisms of polymer nanoparticles in Caco-2 epithelial cells. Biomaterials 34:6082–98
20. R.Hejazi, M.Amiji. (2003). Chitosan-based gastrointestinal delivery systems. J Control Release 89:151–65
21. H.Iyer, A.Khedkar, M.Verma. (2010). Oral insulin – a review of current status. Diabetes Obes Metab 12:179–85
22. Y.Jin, Y.P.Song, X.Zhu,. (2012). Goblet cell-targeting nanoparticles for oral insulin delivery and the influence of mucus on insulin transport. Biomaterials 33:1573–82
23. R.M.Johnson, S.D.Harrison, D.Maclean. (2011). Therapeutic applications of cell-penetrating peptides. Methods Mol Biol 683:535–51
24. N.Kamei, M.Morishita, Y.Eda,. (2008). Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release 132:21–5
25. N.Kamei, Y.Onuki, K.Takayama, M.Takeda-Morishita. (2013). Mechanistic study of the uptake/permeation of cell-penetrating peptides across a Caco-2 monolayer and their stimulatory effect on epithelial insulin transport. J Pharm Sci 102:3998–4008
26. I.M.Kaplan, J.S.Wadia, S.F.Dowdy. (2005). Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 102:247–53
27. T.T.Kararli. (1995). Comparison of the gastrointestinal anatomy physiology, and biochemistry of humans and commonly used laboratory animals. Biopharm Drug Dispos 16:351–80
28. E.-S.KhafagyEl-S, M.Morishita. (2012). Oral biodrug delivery using cell-penetrating peptide. Adv Drug Deliv Rev 64:531–9
29. E.-S.KhafagyEl-S, M.Morishita, Y.Onuki, K.Takayama. (2007). Current challenges in non-invasive insulin delivery systems: a comparative review. Adv Drug Deliv Rev 59:1521–46
30. E.Koren, V.P.Torchilin. (2012). Cell-penetrating peptides: breaking through to the other side. Trends Mol Med 18:385–92
31. A.F.Kotzé, H.L.Lueβen, B.J.De Leeuw,. (1997). N-Trimethyl chitosan chloride as a potential absorption enhancer across mucosal surfaces: in vitro evaluation in intestinal epithelial cells (Caco-2). Pharm Res 14:1197–202
32. X.L.Liu, C.Liu, W.J.Zhang,. (2013). Oligoarginine-modified biodegradable nanoparticles improve the intestinal absorption of insulin. Int J Pharm 448:159–67
33. A.Maroni, L.Zema, M.D.Del Curto,. (2012). Oral colon delivery of insulin with the aid of functional adjuvants. Adv Drug Deliv Rev 64:540–56
34. Y.Masaoka, Y.Tanaka, M.Kataoka,. (2006). Site of drug absorption after oral administration: assessment of membrane permeability and luminal concentration of drugs in each segment of gastrointestinal tract. Eur J Pharm Sci 29:240–50
35. M.E.McGirr, S.M.McAllister, E.E.Peters,. (2009). The use of the InteliSite® companion device to deliver mucoadhesive polymers to the dog colon. Eur J Pharm Sci 36:386–91
36. F.Milletti. (2012). Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov Today 17:850–60
37. M.M.Patel. (2011). Cutting-edge technologies in colon-targeted drug delivery systems. Expert Opin Drug Deliv 8:1247–58
38. M.M.Patel. (2013). Colon targeting: an emerging frontier for oral insulin delivery. Expert Opin Drug Deliv 10:731–9
39. N.A.Peppas, N.J.Kavimandan. (2006). Nanoscale analysis of protein and peptide absorption: insulin absorption using complexation and pH-sensitive hydrogels as delivery vehicles. Eur J Pharm Sci 29:183–97
40. A.K.Philip, B.Philip. (2010). Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J 25:70–8
41. 99mTc-labelled nanosystem as tumour imaging agent for SPECT and SPECT/CT modalities. Int J Pharm 449:10–17
42. S.Reissmann. (2014). Cell penetration: scope and limitations by the application of cell-penetrating peptides. J Pept Sci 20:760–84
43. M.R.Rekha, C.P.Sharma. (2013). Oral delivery of therapeutic protein/peptide for diabetes – future perspectives. Int J Pharm 440:48–62
44. S.Santra, H.Yang, J.T.Stanley,. (2005). Rapid and effective labeling of brain tissue using TAT-conjugated CdS: Mn/ZnS quantum dots. Chem Commun 25:3144–6
45. R.Shelma, C.P.Sharma. (2011). Submicroparticles composed of amphiphilic chitosan derivative for oral insulin and curcumin release applications. Colloids Surf B Biointerfaces 88:722–8
46. C.M.Shi, Y.Zhu, X.Z.Ran,. (2006). Therapeutic potential of chitosan and its derivatives in regenerative medicine. J Surg Res 133:185–92
47. V.R.Sinha, A.Singh, R.V.Kumar,. (2007). Oral colon-specific drug delivery of protein and peptide drugs. Crit Rev Ther Drug Carrier Syst 24:63–92
48. J.S.Skyler. (2007). Prediction and prevention of type 1 diabetes: progress, problems and prospects. Clin Pharmacol Ther 81:768–71
49. R.J.Soane, M.Frier, A.C.Perkins,. (1999). Evaluation of the clearance characteristics of bioadhesive systems in humans. Int J Pharm 178:55–65
50. 99mTc-labeled agent in sentinel lymph node detection. Cancer Biother Radiopharm 28:598–606
51. V.P.Torchilin. (2008). Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 60:548–58
52. A.Trehan, A.Ali. (1998). Recent approaches in insulin delivery. Drug Dev Ind Pharm 24:589–97
53. R.Tréhin, U.Krauss, A.G.Beck-Sickinger,. (2004). Cellular uptake but low permeation of human calcitonin-derived cell penetrating peptides and Tat (47–57) through well-differentiated epithelial models. Pharm Res 21:1248–56
54. G.V.Van den Mooter. (2006). Colon drug delivery. Expert Opin Drug Deliv 3:111–25
55. S.M.Van der Merwe, J.C.Verhoef, J.H.M.Verheijden,. (2004). Trimethylated chitosan as polymeric absorption enhancer for improved peroral delivery of peptide drugs. Eur J Pharm Biopharm 58:225–35
56. F.J.O.Varum, E.L.McConnell, J.J.S.Sousa,. (2008). Mucoadhesion and the gastrointestinal tract. Crit Rev Ther Drug Carrier Syst 25:207–58
57. R.J.Verheul, M.Amidi, S.Van der Wal,. (2008). Synthesis, characterization and in vitro biological properties of O-methyl free N,N,N-trimethylated chitosan. Biomaterials 29:3642–9
58. F.H.Wang, Y.Wang, X.Zhang,. (2014). Recent progress of cell-penetrating peptides as new carriers for intracellular cargo delivery. J Control Release 174:126–36
59. S.Wild, G.Roglic, A.Green,. (2004). Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047–53
60. L.B.Yang, J.S.Chu, J.A.Fix. (2002). Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm 235:1–15
61. L.C.Yin, J.Y.Ding, C.B.He,. (2009). Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 30:5691–700
62. H.Zhang, I.A.Alsarra, S.H.Neau. (2002). An in vitro evaluation of a chitosan-containing multiparticulate system for macromolecule delivery to the colon. Int J Pharm 239:197–205
63. C.Zhang, Y.Ding, Q.N.Ping, L.L.Yu. (2006). Novel chitosan-derived nanomaterials and their micelle-forming properties. J Agric Food Chem 54:8409–16
64. X.Y.Zhang, M.Z.Sun, A.P.Zheng,. (2012). Preparation and characterization of insulin-loaded bioadhesive PLGA nanoparticles for oral administration. Eur J Pharm Sci 45:632–8
65. P.Zhang, X.Z.Zhang, J.Brown,. (2010). Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract 87:293–301